Purpose. To evaluate the changes in living donor liver transplantations (LDLTs) over the last 10 years, we analyzed our experience of performing LDLT in a single center. Methods. We performed 73 LDLTs over the 10 years between 1997 and 2007 in Nagasaki University Hospital, Japan. Results. Initially, from 1997 to 2003, LDLT was performed for pediatric patients; then, between 2004 and 2007, adult-to-adult LDLT was introduced, primarily for hepatocellular carcinoma (HCC) in liver cirrhosis. We also began performing LDLTs for adults with ABOincompatible blood type combination in the latter period. As the number of adult-to-adult LDLTs increased, left-sided grafts became fi rst choice for these patients. Survival rates were 88.3%, 77.2%, 70.2% at 1, 3, and 5 years, respectively. There was a relatively low incidence of arterial complications, and although the incidence of biliary complications was high initially, it decreased with experience. Likewise, the operative time, blood loss, and hospital stay after LDLT also improved remarkably. Conclusion. Over the last 10 years the indications for, and operative techniques used in LDLT have changed dramatically, even in a single center in Japan.
Introduction
Since the fi rst living donor liver transplantation (LDLT) was reported in 1989, this operation has gained widespread recognition as a life-saving treatment, especially in Japan, where deceased donor liver transplantation (DDLT) is not yet accepted. 1, 2 We started our liver transplant program in August 1997 and by August 2007, we had performed 73 LDLTs. Although the liver transplant registry in Japan reports the details of LDLTs annually in the Japanese literature, a detailed analysis to defi ne the changes in LDLT over the past 10 years would be diffi cult, based on a nationwide cohort. Thus, we conducted a retrospective study on LDLT in a single center to evaluate the changes and evolution in this 10-year period.
Patients and Methods

Subjects
The subjects of this retrospective review were 73 patients who underwent LDLT between August 1997 and August 2007 at Nagasaki University Hospital, Japan. The median follow-up of the patients after primary LDLT was 30 months (range 0-123 months). Adult patients are defi ned as those over 16 years old.
Methods
All partial liver grafts were preserved in University of Wisconsin solution and implanted using a piggy-back technique. Surgeons experienced in microscopic surgery anastomosed all of the hepatic arteries with the aid of an operative microscope. In general, graft selection was based on the results of a volumetric study using computed tomography (CT) to obtain a ratio of graft volume to standard liver volume of more than 35% in the recipients. 3 A dual or triple immunosuppressive regimen was used, which included tacrolimus or cyclosporine A, prednisolone, and mycophenolate mofetil. Patients with compromised renal function were given induction therapy with interleukin-2 antibodies. 4 Only biopsyproven rejections were treated if clinical and laboratory signs mandated steroid bolus treatment. Steroid-resistant rejections were treated with OKT3. The following variables were studied: gender, age, original liver disease, indications for LDLT, Child-Pugh and Model for End-Stage Liver Disease (MELD) score at time of LDLT, ABO compatibility, operative blood loss, operative time, and graft type.
Because the Japanese National Health Insurance policy was changed in January 2004 to cover most adult recipients, including those with hepatocellular carcinoma (HCC) within the Milan criteria, we analyzed the indications for LDLT before and after January 2004. Furthermore, as a chief surgeon was appointed for all LDLTs in April 2005, we compared the operative variables before and after April 2005.
Overall patient survival was defi ned as the time in months between LDLT and the death of the patient or the end of the study period, on August 31, 2007. The median follow-up of patients was 29 months (range 0-120 months) for adults and 35 months (0-123 months) for children.
Statistics
Patient survival was calculated with the Kaplan-Meier method. The log-rank test was used to compare survival between groups. Operative variables were compared with a non-parametric test. P values of less than 0.05 were considered signifi cant.
Results
During the second part of the study period, from 2004 to 2007 (n = 45), more adult-to-adult LDLTs were performed than in the fi rst part, from 1997 to 2003 (n = 28), because HCC in a cirrhotic liver caused by viral hepatitis became the main indication for LDLT (Table 1 and Fig. 1) . Accordingly, the donor population changed from "parent to child" to "child to parent." We also began to perform ABO-incompatible combination LDLTs for adult patients (Fig. 2) . Moreover, as the number of adult-to-adult LDLTs increased, left-sided grafts became the fi rst choice in these cases to ensure the safety of donor surgery.
The changes in operative details and management in adult-to-adult LDLTs are summarized in Table 2 . Since pediatric LDLT presents different operative and management challenges than adult LDLT, only cases of adult-to-adult LDLT were compared in this regard. Over the 10 years, blood loss, operative time, and hospital stay improved signifi cantly with better management and advances in operative procedures (P < 0.05).
The overall patient survival rates 1, 3, and 5 years after LDLT were 88.3%, 77.2%, and 70.2%, respectively. There was no difference in patient survival between the adult and pediatric recipients (Fig. 3) . Portal venous complications occurred in two (2.7%) patients in the early phase after LDLT, mainly caused by mechanical and immunological events, whereas in the late phase, six (8.2%) patients suffered complications related to stenosis and thrombus in a portal vein, which were primarily treated with anticoagulation and balloon dilation ( Table 3) .
The results of arterial anastomosis are summarized in Table 4 . Anatomical arterial anastomosis of a graft hepatic artery to a recipient hepatic artery was performed in 65 patients (86.6%), whereas a nonanatomical anastomosis of the side of a recipient artery other than a hepatic artery was performed in ten (13.4%) patients. Arterial complications occurred in six (8.2%) patients, including hepatic artery thrombus (HAT) in three (4.1%). Reanastomosis was performed in fi ve patients, but one of these patients died of a second HAT. Hepatic arterial rupture occurred in one patient, as a result of a pseudoaneurysm after a fungal infection at the anastomotic site.
The methods of biliary reconstruction and their complications are shown in Table 5 . Duct-to-duct anastomosis was performed in 53 (72.6%) patients, most of whom were adults. Biliary complications developed in 14 (19.1%) patients, including anastomotic stricture in 10 (13.7%) patients.
Discussion
Our results show that the indications for LDLT changed dramatically after January 2004 in accordance with the amendments to the National Health Insurance policy in Japan: from being reserved exclusively for pediatric patients and patients with acute disorders to include adult patients with chronic liver failure; most notably, those with HCC secondary to viral hepatitis. Accordingly, the relationship between the living donor and the recipient also changed over this 10-year period. With the extended indications of LDLT for HCC and other chronic liver diseases, the sons and daughters of about half these recipients became partial liver donors to save their parents.
The 5-year survival rate after LDLT has improved to 70%. 1, 5 Moreover, in April 2005, our hospital appointed a senior surgeon to head the liver transplant team. This surgeon is responsible for both recipient and donor surgery and a dedicated LDLT team has developed, which includes surgeons, hepatologists, and nurses, as well as case coordinators. As a team, we have succeeded in reducing the operative time and blood loss, and consequently, the hospital stay after LDLT. Furthermore, the operative technique has been adapted based on updated information from the world literature; for example in relation to the reconstruction of tributaries of the middle hepatic vein, [6] [7] [8] or bile duct assessment in the donor. [9] [10] [11] Interestingly, because of the broader indications for LDLT, which include HCC rather than endstage liver cirrhosis in the latter period, the MELD score of the recipients has become lower than in the former period, which might be a contributing factor to the lower blood loss during surgery.
Improved antiviral therapy has also contributed to the favorable outcome of LDLT; this includes lamivudine, pegylated interferon, and the recent advent of entecavir. 12, 13 There were remarkably more patients with viral-related liver disease in the latter period of this study than in the former period, at 33 vs 5, (13 vs 2 with HBV and 25 vs 3 with HCV), respectively; however, a comparison in survival between the periods was not performed and awaits a longer observation period. An increase in the number of LDLTs performed successfully in ABO blood type-incompatible patients was achieved with the advent of the anti-CD20 antibody (rituximab) to eradicate B cells, which produce the antidonor blood type antibody, and the development of local infusion therapy in Japan. 14, 15 On account of these therapies, the outcomes of LDLT using an ABO-incompatible partial graft have become close to those obtained with an ABO-compatible graft. Naturally, the number of ABO-incompatible LDLTs performed will increase because of the shortage of deceased donor LTs, based on the feasibility of preparing recipients for elective LDLT, by administering rituximab.
The higher incidence of portal venous complications in LDLT may be attributable to the smaller graft size than in whole-liver LT. 16 Late complications developed in six (8.2%) of our patients, but most were treated with anticoagulants and radiological intervention. Three of the four patients with portal venous stenosis were operated on in the former period and had size mismatch in the portal vein between the recipient and donor livers. The other recipient had predisposing portal venous disease in the form of a portal venous aneurysm. Although portal venous complications in pediatric patients have been studied in detail and the incidence calculated at approximately 8% after LDLT, 17 size-mismatched LDLT in adults needs to be analyzed.
Surgery with the aid of an operative microscope has minimized the risks of arterial complications, even though the diameter of each anastomosis is much smaller in LDLT than in DDLT. 18 Moreover, because the arteries are so short, nonanatomical anastomosis is more common in LDLT than in DDLT; however, the short arteries do not increase the incidence of HAT or other problems in arterial anastomosis. Hepatic arterial thrombus requiring reanastomosis developed in three (4.1%) of our patients and this incidence is comparable with those in previous reports on LDLT. 19, 20 Biliary complications are said to be the "Achilles' heel" of LDLT; supported by the fact that they occurred in 19% of our patients. However, with advances in operative procedures in both donors and recipients, and a better understanding of the anatomy, the incidence of biliary complications has been decreasing. Thus, our policy to perform duct-to-duct anastomosis if possible is justifi ed, although the need for tube splints awaits further clinical trials.
In conclusion, the indications for LDLT and its operative techniques have changed dramatically over the last 10 years, even in a single center in Japan. Nevertheless, further refi nement is needed for better postoperative morbidity and mortality.
